Mark Cuban, whose new deal with the Trump administration is already lowering prescription drug costs and expanding access for patients, recently asked why health insurers aren’t liable for malpractice when their denials harm patients. As a physician, I have been asking that question for more than 30 years. The answer is the same now as it was then: No one is holding them accountable. It is time to change that.
Learn More
By Phil Kerpen May 20, 2026 The health insurance companies have taken to the airwaves to blame the hospital systems for out-of-control health care costs. Their argument has some merit, because hospital costs have skyrocketed in recent years. But the insurance companies have been the chief culprits in the cartelization of health care, and it was the Obamacare law they helped shape that was the proximate cause of industrywide consolidation, with a loss of choice…
Learn More
Ten years ago, President Donald Trump put Europe on notice, telling them the status quo on defense spending was unsustainable — and that America would not continue to shoulder the cost of keeping the European Union safe. Trump was right, but leaders such as former German Chancellor Olaf Scholz did not want to listen. Only after Russia’s 2022 invasion of Ukraine did they realize their mistake. Fast forward to 2026, and Scholz’s successor, Friedrich Merz, now aspires to command…
Learn More
Lawmakers in both parties are increasingly embracing the idea of price controls on medicines — and in doing so, they’re making a losing bet. Price controls involve a fundamental tradeoff: lower prices today in exchange for less innovation tomorrow. Consider the “most favored nation,” or MFN, drug pricing proposal currently before Congress. It would cap U.S. drug prices at the lower rates paid in other countries — dramatically undermining the incentives that drive high-risk research…
Learn More
Washington, D.C. – May 20, 2026 – Commitment to Seniors (C2S), a project of American Commitment urges the U.S. Senate to oppose any effort to include the “Most Favored Nation” (MFN) drug pricing model in the upcoming vote-a-rama on Reconciliation 3.0. This foreign price-fixing policy could have a devastating impact on the prescription drug market millions of older Americans rely upon. MFN would import foreign price controls by tying U.S. drug prices to those set…
Learn MoreThe next breakthrough therapy may still be marketed in New York or Basel. But increasingly, it is being born in Shanghai. China’s pharmaceutical industry has moved beyond imitation into something more consequential: early-stage innovation at scale. The clearest signal isn’t manufacturing output or even late-stage approvals. It’s what’s happening at the very front of the pipeline, Phase 1 and Phase 2 clinical trials, where scientific ideas first become viable medicines. By that measure, China is no longer catching up. It…
Learn More
As the health insurance industry continues to face significant headwinds and challenges, the CEOs of major firms largely stayed steady in their compensation for 2025. Based on annual proxy filings from the six major national payers, these executives earned a total of $190.5 million in compensation last year. One of the notable storylines from 2025 was the sudden departure of UnitedHealth Group CEO Andrew Witty in May, and his replacement, Stephen Hemsley, carries a unique…
Learn More
Prescription drug prices keep rising, driven in part by a system in which pharmacy benefit managers (PBMs) sit at the center—controlling which drugs are covered, what pharmacies are paid, and what patients ultimately spend. Yet their profits are tied to higher prices, not lower ones, creating a system where the middleman benefits when costs rise. As long as those incentives remain hidden, patients are left paying the bill with no way to challenge it. Bringing…
Learn More